{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T19:18:35Z","timestamp":1795029515196,"version":"4.10.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-025-11205-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:27:58Z","timestamp":1751372878000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study"],"prefix":"10.1186","volume":"25","author":[{"given":"Sheng-Huei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Cheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuang-Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau-Chyun","family":"Sheu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biing-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yih","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xeng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Kan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-En","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"and the T-CARE (Taiwan Critical Care and Infection) Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"11205_CR1","doi-asserted-by":"crossref","unstructured":"Jesudason T. WHO publishes updated list of bacterial priority pathogens. Lancet Microbe. 2024;5(9):100940.","DOI":"10.1016\/j.lanmic.2024.07.003"},{"issue":"9","key":"11205_CR2","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ajic.2019.03.003","volume":"47","author":"X Du","year":"2019","unstructured":"Du X, Xu X, Yao J, Deng K, Chen S, Shen Z, Yang L, Feng G. Predictors of mortality in patients infected with carbapenem-resistant Acinetobacter baumannii: A systematic review and meta-analysis. Am J Infect Control. 2019;47(9):1140\u20135.","journal-title":"Am J Infect Control"},{"key":"11205_CR3","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Clin Infect Dis. 2023:ciad428.","DOI":"10.1093\/cid\/ciad428"},{"issue":"4","key":"11205_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","volume":"28","author":"M Paul","year":"2022","unstructured":"Paul M, Carrara E, Retamar P, T\u00e4ngd\u00e9n T, Bitterman R, Bonomo RA, de Waele J, Daikos GL, Akova M, Harbarth S, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clinical microbiology and infection\u202f: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2022;28(4):521\u201347.","journal-title":"Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases"},{"issue":"Suppl 2","key":"11205_CR5","doi-asserted-by":"publisher","first-page":"S163","DOI":"10.1093\/cid\/ciad093","volume":"76","author":"RR Watkins","year":"2023","unstructured":"Watkins RR, Bonomo RA. Sulbactam-durlobactam: A Step Forward in Treating Carbapenem-Resistant Acinetobacter baumannii (CRAB) Infections. Clinical infectious diseases\u202f: an official publication of the Infectious Diseases Society of America. 2023;76(Suppl 2):S163-s165.","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"7995","key":"11205_CR6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","volume":"625","author":"C Zampaloni","year":"2024","unstructured":"Zampaloni C, Mattei P, Bleicher K, Winther L, Th\u00e4te C, Bucher C, Adam JM, Alanine A, Amrein KE, Baidin V, et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature. 2024;625(7995):566\u201371.","journal-title":"Nature"},{"key":"11205_CR7","doi-asserted-by":"crossref","unstructured":"Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024:ciae403.","DOI":"10.1093\/cid\/ciae403"},{"issue":"6","key":"11205_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.2165\/00003495-198122060-00002","volume":"22","author":"RN Brogden","year":"1981","unstructured":"Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy. Drugs. 1981;22(6):423\u201360.","journal-title":"Drugs"},{"key":"11205_CR9","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2147\/IDR.S175257","volume":"11","author":"CC Lai","year":"2018","unstructured":"Lai CC, Chen CC, Lu YC, Lin TP, Chuang YC, Tang HJ. Appropriate composites of cefoperazone-sulbactam against multidrug-resistant organisms. Infect Drug Resist. 2018;11:1441\u20135.","journal-title":"Infect Drug Resist"},{"key":"11205_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/IDR.S181201","volume":"12","author":"CC Lai","year":"2019","unstructured":"Lai CC, Chen CC, Lu YC, Chuang YC, Tang HJ. In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Infect Drug Resist. 2019;12:25\u20139.","journal-title":"Infect Drug Resist"},{"issue":"3","key":"11205_CR11","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1128\/AAC.04808-14","volume":"59","author":"WF Penwell","year":"2015","unstructured":"Penwell WF, Shapiro AB, Giacobbe RA, Gu RF, Gao N, Thresher J, McLaughlin RE, Huband MD, DeJonge BL, Ehmann DE, Miller AA. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(3):1680\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"11205_CR12","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zhang J, Chen Y, Wu J, Guo B, Wu X, Zhang Y, Wang M, Ya R, Huang H. Combined PK\/PD Index May Be a More Appropriate PK\/PD Index for Cefoperazone\/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia. Antibiotics (Basel). 2022;11(5):703.","DOI":"10.3390\/antibiotics11050703"},{"key":"11205_CR13","doi-asserted-by":"crossref","unstructured":"Kogilathota Jagirdhar GS, Rama K, Reddy ST, Pattnaik H, Qasba RK, Elmati PR, Kashyap R, Schito M, Gupta N. Efficacy of Cefoperazone Sulbactam in Patients with Acinetobacter Infections: A Systematic Review of the Literature. Antibiotics (Basel). 2023;12(3):582.","DOI":"10.3390\/antibiotics12030582"},{"issue":"12","key":"11205_CR14","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1111\/j.1469-0691.2011.03514.x","volume":"17","author":"O Zarkotou","year":"2011","unstructured":"Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, Prekates A, Themeli-Digalaki K, Tsakris A. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17(12):1798\u2013803.","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"11205_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","volume":"46","author":"JF Timsit","year":"2020","unstructured":"Timsit JF, Rupp\u00e9 E, Barbier F, Tabah A, Bassetti M. Bloodstream infections in critically ill patients: an expert statement. Intensive Care Med. 2020;46(2):266\u201384.","journal-title":"Intensive Care Med"},{"key":"11205_CR16","doi-asserted-by":"crossref","unstructured":"Sihler KC, Chenoweth C, Zalewski C, Wahl W, Hyzy R, Napolitano LM: Catheter-related vs. catheter-associated blood stream infections in the intensive care unit: incidence, microbiology, and implications. Surg Infect (Larchmt). 2010, 11(6):529\u2013534.","DOI":"10.1089\/sur.2009.084"},{"issue":"5","key":"11205_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.7326\/0003-4819-132-5-200003070-00009","volume":"132","author":"LA Mermel","year":"2000","unstructured":"Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med. 2000;132(5):391\u2013402.","journal-title":"Ann Intern Med"},{"key":"11205_CR18","doi-asserted-by":"crossref","unstructured":"Renaud B, Brun-Buisson C: Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respirat Crit Care Med. 2001, 163(7):1584\u20131590.","DOI":"10.1164\/ajrccm.163.7.9912080"},{"key":"11205_CR19","doi-asserted-by":"crossref","unstructured":"Weinstein MP, Lewis JS, 2nd. The Clinical and Laboratory Standards Institute Subcommittee on Antimicrobial Susceptibility Testing: Background, Organization, Functions, and Processes. J Clin Microbiol. 2020;58(3):e01864\u201319.","DOI":"10.1128\/JCM.01864-19"},{"issue":"10","key":"11205_CR20","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.cmi.2021.01.020","volume":"27","author":"JY Feng","year":"2021","unstructured":"Feng JY, Peng CK, Sheu CC, Lin YC, Chan MC, Wang SH, Chen CM, Shen YC, Zheng ZR, Lin YT, Yang KY. Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant Gram-negative bacterial pneumonia: a multi-centre observational study. Clin Microbiol Infect. 2021;27(10):1465\u201373.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"11205_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13054-022-03947-9","volume":"26","author":"SH Wang","year":"2022","unstructured":"Wang SH, Yang KY, Sheu CC, Chen WC, Chan MC, Feng JY, Chen CM, Wu BR, Zheng ZR, Chou YC, Peng CK. The necessity of a loading dose when prescribing intravenous colistin in critically ill patients with CRGNB-associated pneumonia: a multi-center observational study. Crit Care. 2022;26(1):91.","journal-title":"Crit Care"},{"issue":"2","key":"11205_CR22","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/pst.433","volume":"10","author":"PC Austin","year":"2011","unstructured":"Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2):150\u201361.","journal-title":"Pharm Stat"},{"key":"11205_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13756-019-0502-x","volume":"8","author":"T Niu","year":"2019","unstructured":"Niu T, Luo Q, Li Y, Zhou Y, Yu W, Xiao Y. Comparison of Tigecycline or Cefoperazone\/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii. Antimicrob Resist Infect Control. 2019;8:52.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"1","key":"11205_CR24","first-page":"37","volume":"7","author":"JK Noguchi","year":"1988","unstructured":"Noguchi JK, Gill MA. Sulbactam: a beta-lactamase inhibitor. Clin Pharm. 1988;7(1):37\u201351.","journal-title":"Clin Pharm"},{"issue":"1","key":"11205_CR25","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00800-23","volume":"68","author":"J O'Donnell","year":"2024","unstructured":"O\u2019Donnell J, Tanudra A, Chen A, Newman J, McLeod SM, Tommasi R. In vivo dose response and efficacy of the \u03b2-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex. Antimicrob Agents Chemother. 2024;68(1): e0080023.","journal-title":"Antimicrob Agents Chemother"},{"key":"11205_CR26","doi-asserted-by":"crossref","unstructured":"Beganovic M, Daffinee KE, Luther MK, LaPlante KL. Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model. Antimicrob agents chemother. 2021;65(3):e01680\u201320.","DOI":"10.1128\/AAC.01680-20"},{"issue":"4","key":"11205_CR27","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/jac\/47.4.479","volume":"47","author":"MJ Rodr\u00edguez-Hern\u00e1ndez","year":"2001","unstructured":"Rodr\u00edguez-Hern\u00e1ndez MJ, Cuberos L, Pichardo C, Caballero FJ, Moreno I, Jim\u00e9nez-Mej\u00edas ME, Garc\u00eda-Curiel A, Pach\u00f3n J. Sulbactam efficacy in experimental models caused by susceptible and intermediate Acinetobacter baumannii strains. J Antimicrob Chemother. 2001;47(4):479\u201382.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"11205_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13054-017-1916-6","volume":"21","author":"SY Jung","year":"2017","unstructured":"Jung SY, Lee SH, Lee SY, Yang S, Noh H, Chung EK, Lee JI. Antimicrobials for the treatment of drug-resistant Acinetobacter baumannii pneumonia in critically ill patients: a systemic review and Bayesian network meta-analysis. Crit Care. 2017;21(1):319.","journal-title":"Crit Care"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11205-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11205-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T12:28:04Z","timestamp":1751372884000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11205-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11205"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11205-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Boards (IRBs) of five hospitals and followed the ethical principles of the Declaration of Helsinki. The IRB registration numbers were A202005146 (Institutional Review Board of Tri-Service General Hospital, National Defense Medical Center), CMUH110-REC1-139 (China Medical University & Hospital Research Ethics Center), CE18100A (the Institutional Review Board of Taichung Veterans General Hospital), 2020\u201311-006AC (Institutional Review Board of the Taipei Veterans General Hospital), and KMUHIRB-E(I)-20180141 (Institutional Review Board of Kaohsiung Medical University Hospital). The need for informed consent to participate was waived by the IRB of each hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"872"}}